BioCentury | Feb 25, 2021
Deals

Feb. 24 Quick Takes: ICON buying PRA in $12B CRO deal; plus venture rounds for Yisheng, Xilio, Truvian, Lyvgen, AmacaThera, and more

...By Jeff Cranmer, Executive Editor ICON plc (NASDAQ:ICLR) is buying fellow CRO PRA Health Sciences Inc. (NASDAQ:PRAH...
...an AI-enabled cell culture media development platform. Staff Writer Hongjiang Li contributed to this report. Jeff Cranmer ICON plc PRA...
BioCentury | Feb 23, 2021
Product Development

Pipeline plays for BMS, Rigel; plus J&J’s vaccine panel & access for Africa: a BioCentury podcast

...kinase 4RIPK1 (RIP1) - Receptor-interacting serine-threonine kinase 1 Jeff Cranmer Johnson & Johnson Rigel Pharmaceuticals Inc. Bristol Myers Squibb Co. ICON plc Janet...
BioCentury | Feb 17, 2021
Product Development

Start-up trends, COVID variants and J&J’s adcomm: a BioCentury podcast

...podcasts and surveys. For more information, please contact Eric Pierce and Josh Berlin at conferences@biocentury.com. BC Staff ICON plc covid-19 cov19count bee2021 cov19count...
BioCentury | Oct 15, 2020
Product Development

What clinical holds and pauses mean for COVID-19 countermeasure timelines

...be reported to health authorities,” said David Morse, VP of global regulatory affairs at CRO ICON plc...
BioCentury | Dec 4, 2019
Company News

Dec. 3 Company Quick Takes: Brii adds neuroscience focus; plus Immunomedics, Hanmi-Rapt, Luye-Boan and Cara

...GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), Kraus was most recently VP of drug development services at CRO Icon plc...
BioCentury | Oct 15, 2019
Company News

Management tracks: Gilead taps Dickinson for CFO job; plus Checkmate, BiomX, Anixa and Trio

...company Trio Health hired Ramita Tandon as COO. She was EVP commercialization and outcomes at ICON plc...
BioCentury | Jul 13, 2019
Product Development

Moving Beyond a Buzzword: How small- to mid-sized biotechs can adopt patient centricity in oncology trials

...reflect the views of the authors, not necessarily those of BioCentury. Companies and Institutions Mentioned ICON plc...
...Clossick Thomson, Senior Director of Oncology Project Management, and Susan Campbell, Director of Patient Recruitment, ICON plc FDA ICON plc patient...
BioCentury | Sep 5, 2016
Strategy

Back to School 2016: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
BioCentury | Aug 3, 2015
Finance

From Phase4 to Mereo

...do is help us put this together,'" said Scots-Knight. The team opted to work with ICON plc...
...Inc. Companies and Institutions Mentioned Albireo AB, Gothenburg, Sweden AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. ICON plc...
BioCentury | Jul 30, 2015
Top Story

Mereo raises $119M, acquires three Novartis programs<span class="*Red-type+bold">

...for first-line therapy of obese men with hypogonadotrophic hypogonadism. Mereo has also partnered with CRO ICON plc...
Items per page:
1 - 10 of 23
BioCentury | Feb 25, 2021
Deals

Feb. 24 Quick Takes: ICON buying PRA in $12B CRO deal; plus venture rounds for Yisheng, Xilio, Truvian, Lyvgen, AmacaThera, and more

...By Jeff Cranmer, Executive Editor ICON plc (NASDAQ:ICLR) is buying fellow CRO PRA Health Sciences Inc. (NASDAQ:PRAH...
...an AI-enabled cell culture media development platform. Staff Writer Hongjiang Li contributed to this report. Jeff Cranmer ICON plc PRA...
BioCentury | Feb 23, 2021
Product Development

Pipeline plays for BMS, Rigel; plus J&J’s vaccine panel & access for Africa: a BioCentury podcast

...kinase 4RIPK1 (RIP1) - Receptor-interacting serine-threonine kinase 1 Jeff Cranmer Johnson & Johnson Rigel Pharmaceuticals Inc. Bristol Myers Squibb Co. ICON plc Janet...
BioCentury | Feb 17, 2021
Product Development

Start-up trends, COVID variants and J&J’s adcomm: a BioCentury podcast

...podcasts and surveys. For more information, please contact Eric Pierce and Josh Berlin at conferences@biocentury.com. BC Staff ICON plc covid-19 cov19count bee2021 cov19count...
BioCentury | Oct 15, 2020
Product Development

What clinical holds and pauses mean for COVID-19 countermeasure timelines

...be reported to health authorities,” said David Morse, VP of global regulatory affairs at CRO ICON plc...
BioCentury | Dec 4, 2019
Company News

Dec. 3 Company Quick Takes: Brii adds neuroscience focus; plus Immunomedics, Hanmi-Rapt, Luye-Boan and Cara

...GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), Kraus was most recently VP of drug development services at CRO Icon plc...
BioCentury | Oct 15, 2019
Company News

Management tracks: Gilead taps Dickinson for CFO job; plus Checkmate, BiomX, Anixa and Trio

...company Trio Health hired Ramita Tandon as COO. She was EVP commercialization and outcomes at ICON plc...
BioCentury | Jul 13, 2019
Product Development

Moving Beyond a Buzzword: How small- to mid-sized biotechs can adopt patient centricity in oncology trials

...reflect the views of the authors, not necessarily those of BioCentury. Companies and Institutions Mentioned ICON plc...
...Clossick Thomson, Senior Director of Oncology Project Management, and Susan Campbell, Director of Patient Recruitment, ICON plc FDA ICON plc patient...
BioCentury | Sep 5, 2016
Strategy

Back to School 2016: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
BioCentury | Aug 3, 2015
Finance

From Phase4 to Mereo

...do is help us put this together,'" said Scots-Knight. The team opted to work with ICON plc...
...Inc. Companies and Institutions Mentioned Albireo AB, Gothenburg, Sweden AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. ICON plc...
BioCentury | Jul 30, 2015
Top Story

Mereo raises $119M, acquires three Novartis programs<span class="*Red-type+bold">

...for first-line therapy of obese men with hypogonadotrophic hypogonadism. Mereo has also partnered with CRO ICON plc...
Items per page:
1 - 10 of 23